1. Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract. 2005; 59:1091–1096.
2. Hutchison AJ, Wilson RJ, Garafola S, et al. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton). 2016; 21:987–994.
3. Makino M, Kawaguchi K, Shimojo H, et al. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int. 2015; 65:33–37.
4. Iwamuro M, Urata H, Tanaka T, et al. Review of the diagnosis of gastrointestinal lanthanum deposition. World J Gastroenterol. 2020; 26:1439–1449.
5. Kim SY, Lee JH, Lee SK. Gastric mucosal calcinosis. Korean J Gastroenterol. 2017; 70:208–210.
6. Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver. 2021; 15:646–652.
7. Kim GH. Clinicians should be aware of proton pump inhibitor-related changes in the gastric mucosa. Clin Endosc. 2024; 57:51–52.
9. Nishida S, Ota K, Hattori K, et al. Investigation of the clinical significance and pathological features of lanthanum deposition in the gastric mucosa. BMC Gastroenterol. 2020; 20:396.
10. Nakamura T, Tsuchiya A, Kobayashi M, et al. M2-polarized macrophages relate the clearance of gastric lanthanum deposition. Clin Case Rep. 2019; 7:570–572.